Hopp til hovedinnhold

Guillain-Barré syndrom (AIDP)

Sist oppdatert: Sist revidert:
Sist revidert av:
Definisjon:
Akutt perifer polynevropati av autoimmun årsak. Oftest forutgått av infeksjonssykdom.
Forekomst:
1-2 tilfeller per 100.000 personer per år
Symptomer:
Akutt innsettende svakhetsfølelse, nummenhet, parestesier og smerter i ekstremiteter, symmetrisk lokalisert
Funn:
Pareser og svekkede reflekser, nedsatt perifer sensibilitet.
Diagnostikk:
Klinisk diagnose, men bekreftes ved måling av nerveledning
Behandling:
Sykehusinnleggelse med overvåkning av vitale funksjoner. Likeverdige behandlingsalternativer er intravenøs immunglobulin eller plasmaferese.
  1. Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician 2013; 87: 191-7. American Family Physician  
  2. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology 2019; 15: 671–683 .
  3. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Seminar. Lancet 2021; 397: 1214-28. doi:10.1016/S0140-6736(21)00517-1 DOI  
  4. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011; 36: 123-33. PubMed  
  5. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. Epub 2016 Mar 2. pmid: 2694843 PubMed  
  6. Leonhard SE, van der Eijk AA, Andersen H, et al. An International Perspective on Preceding Infections in Guillain-Barré Syndrome The IGOS-1000 Cohort. Neurology 2022. pmid:35981895 PubMed  
  7. Rocha Cabrero F, Morrison EH. Miller Fisher syndrome. 2021. In StatPearls. Treasure Island, FL StatPearls Publishing 2021. www.ncbi.nlm.nih.gov  
  8. Hughes RAC, Swan AV, Raphaël JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130: 2245-57. PubMed  
  9. Rudolph T, Larsen JP, Farbu E. The long-term functional status in patients with Guillain-Barré syndrome. Eur J Neurol. 2008 Dec. 15(12):1332-7.
  10. Cohen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM-sleep in Guillain-Barré syndrome. Brain 2005; 128: 2535-45. PubMed  
  11. Nobuhiro Y, Hartung H-P. Guillain-Barré syndrome. N Engl J Med 2012; 366: 2294-304. New England Journal of Medicine  
  12. Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Arch Neurol 2001; 58: 913-7. PubMed  
  13. Winer JB. Guillain-Barre syndrom. Clinical review. BMJ 2008; 337: a671. PubMed  
  14. Gorson KC, Ropper AH, Muriello MA, et al. Prospective evaluation of MRI lumbosacral root enhancement in acute Guillain–Barré syndrome. Neurology 1996; 47: 813–17.
  15. Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61: 736-40. Neurology  
  16. Vriesendorp FJ. Guillain-Barré syndrome in adults: Clinical features and diagnosis. UpToDate, last updated Dec 04, 2018. UpToDate  
  17. Gerdts R, Jensen D, Fauchald P, Skjeldal O, Guillain-Barré Syndrome. Moderne behandlingsprinsipper belyst ved et klinisk materiale, Tidsskr Nor lægeforen 1999; 119: 506-9
  18. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No.: CD002063. DOI: 10.1002/14651858.CD002063.pub6. DOI  
  19. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD001798. DOI: 10.1002/14651858.CD001798.pub2. DOI  
  20. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446 . pmid:27775812 PubMed  
  21. van Koningsveld R, Schmitz PIM, van der Meché FGA, et al. Effect of methylprednisolone when added to standard treatement with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004; 363: 192-6. PubMed  
  22. The prognosis and main prognostic indicators of Guillain-Barré syndrome: a multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group. Brain 1996; 119(pt 6): 2053-61.
  23. Korinthenberg R, Monting JS. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Arch Dis Child 1996; 74: 281. PubMed  
  24. NevroNEL. Guillain-Barré syndrom. Norsk Nevrologisk Forening. Sist oppdatert sept. 2020. Siden lest 07.04.2021 nevrologi.legehandboka.no  
  25. Lawn ND, Wijdicks EF. Fatal Guillain-Barré syndrome. Neurology 1999; 52: 635-8. Neurology  
  26. Khan F, Pallant JF, Ng L, Bhasker A. Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J Neurol. 2010 Dec. 257(12):2024-31.
  27. Das A, Kalita J, Misra UK. Recurrent Guillain Barre' syndrome. Electromyogr Clin Neurophysiol. 2004 Mar. 44(2):95-102.
  • Rune Midgard, dr. med., overlege og førsteamanuensis II emeritus, NTNU
  • Ingard Løge, spesialist allmennmedisin, Trondheim

Tidligere fagmedarbeidere

  • Espen Dietrichs, professor og avdelingsoverlege, Universitetet i Oslo og Nevrologisk avdeling, Rikshospitalet, Oslo